• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗反应和几项患者报告的结局是类风湿关节炎患者未来自我效能感的早期决定因素。

Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.

机构信息

Department of Development and Regeneration, KU Leuven, Skeletal Biology and Engineering Research Centre, ON IV Herestraat 49 - bus 805, 3000, Leuven, Belgium.

Rheumatology, University Hospitals Leuven, Leuven, Belgium.

出版信息

Arthritis Res Ther. 2021 Oct 27;23(1):269. doi: 10.1186/s13075-021-02651-3.

DOI:10.1186/s13075-021-02651-3
PMID:34706771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8549201/
Abstract

BACKGROUND

Self-efficacy, or patients' confidence in their ability to control disease and its consequences, was recently prioritised in EULAR recommendations for inflammatory arthritis self-management strategies. However, it remains unclear which factors influence self-efficacy in early rheumatoid arthritis (RA).

METHODS

Data were analysed from the 2-year RCT Care in early RA (CareRA), which studied remission-induction treatment regimens for early RA. Participants completed the Arthritis Self-Efficacy Scale (ASES), Short-Form 36 (SF-36), Revised Illness Perception Questionnaire (IPQ-R), Utrecht Coping List (UCL), RAQoL and Health Assessment Questionnaire (HAQ). Depending on time to first remission (DAS28-CRP < 2.6) and persistence of remission, treatment response was defined as persistent response, secondary failure, delayed response, late response or non-response. The association between ASES scores and clinical/psychosocial factors was explored with Spearman correlation and multivariate linear mixed models. Baseline predictors of week 104 ASES were identified with exploratory linear regression followed by multiple regression of significant predictors adjusted for DAS28-CRP, HAQ, treatment arm, treatment response, cumulative CRP/SJC28 and demographic/serologic confounders.

RESULTS

All 379 patients had a recent diagnosis of RA and were DMARD-naïve at study initiation. Most patients were women (69%) and RF/ACPA-positive (66%), and the mean (SD) age was 52 (13) years. For all tested outcome measures, better perceived health correlated with higher self-efficacy. While patient-reported factors (HAQ, SF-36, RAQoL, IPQ-R, pain, fatigue and patient's global assessment) showed moderate/strong correlations with ASES scores, correlations with physician-reported factors (physician's global assessment, SJC28), TJC28 and DAS28-CRP were weak. Only more favourable outcomes on patient-reported factors and DAS28-CRP were associated with higher ASES scores at each time point. An earlier, persistent treatment response predicted higher ASES scores at both weeks 52 and 104. Significant baseline predictors of week 104 ASES included HAQ; SF-36 mental component score, vitality, mental health and role emotional; IPQ-R illness coherence, treatment control, emotional representations and consequences; UCL Passive reacting; and the RAQoL.

CONCLUSIONS

Patient-reported outcomes and treatment response were early determinants of long-term self-efficacy in an early RA trial. These results provide further relevance for the window of opportunity in an early treat-to-target strategy and could help to timely identify patients who might benefit from self-management interventions.

TRIAL REGISTRATION

EudraCT 2008-007225-39.

摘要

背景

自我效能感,即患者对控制疾病及其后果的能力的信心,最近在 EULAR 对炎症性关节炎自我管理策略的建议中被列为优先事项。然而,在早期类风湿关节炎(RA)中,哪些因素影响自我效能感仍不清楚。

方法

对 2 年 RCT Care in early RA(CareRA)的数据进行了分析,该研究研究了早期 RA 的缓解诱导治疗方案。参与者完成了关节炎自我效能量表(ASES)、简短 36 项健康调查(SF-36)、修订后的疾病感知问卷(IPQ-R)、乌得勒支应对清单(UCL)、RAQoL 和健康评估问卷(HAQ)。根据首次缓解的时间(DAS28-CRP<2.6)和缓解的持续时间,治疗反应定义为持续反应、继发性失败、延迟反应、晚期反应或无反应。使用 Spearman 相关和多元线性混合模型探讨了 ASES 评分与临床/心理社会因素之间的关系。使用探索性线性回归确定了第 104 周 ASES 的基线预测因子,然后使用多元回归对 DAS28-CRP、HAQ、治疗臂、治疗反应、累积 CRP/SJC28 和人口统计学/血清学混杂因素进行调整后,对显著预测因子进行了回归。

结果

所有 379 名患者均在最近诊断为 RA 且在研究开始时为 DMARD 初治。大多数患者为女性(69%)和 RF/ACPA 阳性(66%),平均(SD)年龄为 52(13)岁。对于所有测试的结果测量,感知到的健康状况越好,自我效能感越高。虽然患者报告的因素(HAQ、SF-36、RAQoL、IPQ-R、疼痛、疲劳和患者的整体评估)与 ASES 评分呈中度/强相关,但与医生报告的因素(医生的整体评估、SJC28)、TJC28 和 DAS28-CRP 的相关性较弱。只有患者报告的因素和 DAS28-CRP 更有利的结果与每个时间点的 ASES 评分更高相关。更早、持续的治疗反应预测了第 52 周和第 104 周时 ASES 评分更高。第 104 周 ASES 的显著基线预测因子包括 HAQ;SF-36 心理成分评分、活力、心理健康和情绪角色;IPQ-R 疾病一致性、治疗控制、情绪表现和后果;UCL 被动反应;和 RAQoL。

结论

在早期 RA 试验中,患者报告的结果和治疗反应是长期自我效能感的早期决定因素。这些结果为早期治疗目标策略的机会窗口提供了进一步的相关性,并可能有助于及时识别可能从自我管理干预中受益的患者。

试验注册

EudraCT 2008-007225-39。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be06/8549201/6424ab900eb4/13075_2021_2651_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be06/8549201/64a8a4b078ab/13075_2021_2651_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be06/8549201/6424ab900eb4/13075_2021_2651_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be06/8549201/64a8a4b078ab/13075_2021_2651_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be06/8549201/6424ab900eb4/13075_2021_2651_Fig2_HTML.jpg

相似文献

1
Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.治疗反应和几项患者报告的结局是类风湿关节炎患者未来自我效能感的早期决定因素。
Arthritis Res Ther. 2021 Oct 27;23(1):269. doi: 10.1186/s13075-021-02651-3.
2
Psychosocial Burden Predicts Sustained Remission in Early Rheumatoid Arthritis: Unraveling the Complex Interplay of Well-Being and Disease Activity.心理社会负担可预测早期类风湿关节炎的持续缓解:揭示幸福感与疾病活动之间的复杂相互作用。
Arthritis Care Res (Hoboken). 2023 Apr;75(4):758-767. doi: 10.1002/acr.24847. Epub 2022 Nov 28.
3
Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach.患者报告结局作为采用严格控制达标治疗方法治疗的早期类风湿关节炎患者缓解的预测指标。
Rheumatol Int. 2017 May;37(5):825-830. doi: 10.1007/s00296-017-3692-7. Epub 2017 Mar 13.
4
Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial.在早期类风湿性关节炎管理中,疾病认知和应对方式与症状出现到首次全科医生咨询之间的延迟有关吗?CareRA试验中的一项探索性研究。
Scand J Rheumatol. 2016;45(3):171-8. doi: 10.3109/03009742.2015.1074278. Epub 2015 Sep 23.
5
Patient-Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for Broadening the Scope of Treating to Target.早期类风湿关节炎试验的患者报告结局数据:拓宽靶向治疗范围的机会。
Arthritis Care Res (Hoboken). 2019 Dec;71(12):1566-1575. doi: 10.1002/acr.23900.
6
The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.在类风湿关节炎注册研究中,生物制剂使用对患者结局(疾病活动度、功能和疾病严重程度)的纵向影响。
Clin Rheumatol. 2019 Nov;38(11):3081-3092. doi: 10.1007/s10067-019-04649-4. Epub 2019 Jul 29.
7
Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.在 DAS28 缓解的类风湿关节炎患者中疼痛持续存在,但在 ACR/EULAR 缓解的患者中则没有:一项纵向观察性研究。
Arthritis Res Ther. 2011 Jun 8;13(3):R83. doi: 10.1186/ar3353.
8
Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.患者报告结局作为早期类风湿关节炎疾病活动度和残疾变化的预测指标:来自约克郡早期关节炎登记处的结果。
J Rheumatol. 2017 Sep;44(9):1331-1340. doi: 10.3899/jrheum.161214. Epub 2017 Jul 1.
9
Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.DE020 研究的最终 10 年疗效和安全性结果:阿达木单抗治疗对标准治疗反应不足的类风湿关节炎患者。
Rheumatology (Oxford). 2015 Dec;54(12):2188-97. doi: 10.1093/rheumatology/kev249. Epub 2015 Jul 21.
10
Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.肿瘤坏死因子抑制剂对比传统改善病情抗风湿药物联合强化治疗用于确诊类风湿关节炎的随机对照试验:TACIT试验及相关系统评价
Health Technol Assess. 2014 Oct;18(66):i-xxiv, 1-164. doi: 10.3310/hta18660.

引用本文的文献

1
An Exploration of Self-Efficacy and Its Associated Factors among Rheumatoid Arthritis Patients in Taiwan.台湾类风湿关节炎患者自我效能及其相关因素探讨。
Medicina (Kaunas). 2024 Oct 9;60(10):1653. doi: 10.3390/medicina60101653.
2
Efficacy of a cognitive-behavioral digital therapeutic on psychosocial outcomes in rheumatoid arthritis: randomized controlled trial.认知行为数字疗法对类风湿关节炎心理社会结局的疗效:随机对照试验
Npj Ment Health Res. 2024 Sep 3;3(1):41. doi: 10.1038/s44184-024-00085-8.
3
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial.

本文引用的文献

1
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.2021 年 EULAR 炎症性关节炎患者自我管理策略实施建议。
Ann Rheum Dis. 2021 Oct;80(10):1278-1285. doi: 10.1136/annrheumdis-2021-220249. Epub 2021 May 7.
2
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.在 CareRA 试验中,对于类风湿关节炎患者,甲氨蝶呤诱导治疗联合或不联合其他 csDMARDs 和临时糖皮质激素的 5 年达标治疗结果。
Ann Rheum Dis. 2021 Aug;80(8):965-973. doi: 10.1136/annrheumdis-2020-219825. Epub 2021 Apr 2.
3
甲氨蝶呤联合或不联合早期引入为期6个月的依那西普疗程的桥接糖皮质激素在早期类风湿关节炎中的疗效:为期2年的实用随机CareRA2020试验结果
RMD Open. 2024 Aug 7;10(3):e004535. doi: 10.1136/rmdopen-2024-004535.
4
The effect of a self-management program on the quality of life of patients with scleroderma.自我管理项目对硬皮病患者生活质量的影响。
J Educ Health Promot. 2024 Jan 22;12:440. doi: 10.4103/jehp.jehp_1690_22. eCollection 2023.
5
Effectiveness and feasibility of a mobile health self-management intervention in rheumatoid arthritis: study protocol for a pragmatic multicentre randomised controlled trial (AEGORA).移动健康自我管理干预类风湿关节炎的效果和可行性:一项实用、多中心、随机对照试验的研究方案(AEGORA)。
Trials. 2023 Oct 28;24(1):697. doi: 10.1186/s13063-023-07733-y.
6
An engineered glove to follow finger function in rheumatoid arthritis: an observational prospective study.一种用于类风湿关节炎手指功能的工程手套:一项观察性前瞻性研究。
Rheumatol Int. 2024 Feb;44(2):307-318. doi: 10.1007/s00296-023-05444-w. Epub 2023 Sep 13.
7
Demographic, Physical, and Psychological Determinants of Patient Experience with Subcutaneous Self-Injection in Patients with Rheumatoid Arthritis: Structural Equation Modeling Approach.类风湿关节炎患者皮下自我注射患者体验的人口统计学、身体和心理决定因素:结构方程建模方法
Patient Prefer Adherence. 2023 Jul 3;17:1551-1559. doi: 10.2147/PPA.S413871. eCollection 2023.
8
Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients.类风湿关节炎患者传统合成改善病情抗风湿药(csDMARDs)临床反应预测列线图的建立、验证及初步研究
Ann Transl Med. 2022 Dec;10(24):1365. doi: 10.21037/atm-22-5791.
9
How long does it take to translate research findings into routine healthcare practice?-the case of biological drugs for rheumatoid arthritis in Brazil.将研究成果转化为常规医疗实践需要多长时间?——以巴西类风湿关节炎生物药物为例。
Ann Transl Med. 2022 Jul;10(13):738. doi: 10.21037/atm-22-397.
10
Correction to: Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.对《类风湿关节炎的治疗反应和若干患者报告结局是未来自我效能感的早期决定因素》的更正
Arthritis Res Ther. 2021 Nov 15;23(1):285. doi: 10.1186/s13075-021-02669-7.
One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment.
五分之一的早期类风湿关节炎患者在接受快速和持续控制治疗 1 年后报告身体不适。
RMD Open. 2020 Apr;6(1). doi: 10.1136/rmdopen-2019-001146.
4
New galaxies in the universe of shared decision-making and rheumatoid arthritis.宇宙中的新星系在于共同决策和类风湿性关节炎。
Curr Opin Rheumatol. 2020 May;32(3):273-278. doi: 10.1097/BOR.0000000000000699.
5
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.EULAR 推荐的类风湿关节炎治疗策略:2019 年更新版(使用合成和生物疾病修正抗风湿药物)
Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.
6
Self-Efficacy and the Role of Non-Pharmacologic Treatment Strategies to Improve Pain and Affect in Arthritis.自我效能与非药物治疗策略在改善关节炎疼痛及情感方面的作用
Curr Treatm Opt Rheumatol. 2019 Jun 15;5:168-178. doi: 10.1007/s40674-019-00123-z. Epub 2019 Apr 30.
7
Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.不同 DMARDs 和糖皮质激素桥接联合方案在早期类风湿关节炎中的疗效:CareRA 的两年结果。
Rheumatology (Oxford). 2019 Dec 1;58(12):2284-2294. doi: 10.1093/rheumatology/kez213.
8
Arthritis self-efficacy beliefs and functioning among osteoarthritis and rheumatoid arthritis patients: a meta-analytic review.骨关节炎和类风湿关节炎患者的关节炎自我效能信念和功能:荟萃分析综述。
Rheumatology (Oxford). 2020 May 1;59(5):948-958. doi: 10.1093/rheumatology/kez219.
9
Patient-Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for Broadening the Scope of Treating to Target.早期类风湿关节炎试验的患者报告结局数据:拓宽靶向治疗范围的机会。
Arthritis Care Res (Hoboken). 2019 Dec;71(12):1566-1575. doi: 10.1002/acr.23900.
10
Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT).减少关节炎疲劳的影响:风湿科团队的认知行为方法(RAFT)两年随机对照试验。
Ann Rheum Dis. 2019 Apr;78(4):465-472. doi: 10.1136/annrheumdis-2018-214469. Epub 2019 Feb 6.